Edgewise Therapeutics (EWTX)
Developer of sarcomere modulators for hypertrophic cardiomyopathy and heart failure.
Something off on this page? Send us feedback.
Develops oral small-molecule sarcomere modulators for hypertrophic cardiomyopathy, heart failure and other cardiovascular or cardiometabolic diseases. Following the completed sale of its muscular dystrophy business, the pipeline centers on EDG-7500, EDG-15400 and EDG-003; no product is approved, so the business depends on clinical and regulatory progress.
Develops oral small-molecule therapies that modulate muscle sarcomere proteins, now concentrating on cardiovascular disease after completing the sale of sevasemten and its muscular dystrophy business to Servier. EDG-7500 is being studied in obstructive and non-obstructive hypertrophic cardiomyopathy, while EDG-15400 is being developed for heart failure with preserved ejection fraction. EDG-003 addresses an undisclosed cardiovascular or cardiometabolic target.
Combines muscle biology, small-molecule engineering and integrated muscle-function assays to discover and advance sarcomere modulators. Research and development are managed as one segment, with operations and fixed assets in the United States.
Has no approved products and generates no product revenue. Future operations depend on clinical-trial results, regulatory approvals, intellectual-property protection and third parties that manufacture drug candidates.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $45 | Target: $57 |
| Aug 11, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $32 | Target: $36 |
| Jul 20, 2026 | Evercore ISI | Reiterate | Rating: —Target: $45 | Target: $55 |
| Jul 9, 2026 | Oppenheimer | Initiate | Rating: —Target: — | Target: $51 |
| Jul 6, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $51 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $460.7M · Total debt $3.6M · Total assets $479.7M · Shareholders' equity $448.1M
- Revenue
- $0
- Operating income
- −$61.9M
- Net income
- −$57.3M
No dividends on record.
| Institutions | 110.32% | 119.82M shares | |
|---|---|---|---|
| 238 holders · as of Jun 30, 2026 | |||
| Insiders | 0.26% | 279.6K shares | |
| 9 holders · as of Aug 14, 2026 | |||
| Strategic holders | 5.45% | 5.92M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 116.03% | ||
108.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 116.03%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Orbimed Advisors LLCInstitution | 14.29% | 15.52M | as of Jun 30, 2026 |
Paradigm Biocapital Advisors LPInstitution | 9.41% | 10.22M | as of Jun 30, 2026 |
Ra Capital Management, L.P.Institution | 7.73% | 8.39M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.08% | 6.61M | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 5.59% | 6.08M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Kevin Koch | director, officer: President and CEO | −17,971 | $43.68 |
| Aug 12, 2026 | Behrad Derakhshan | officer: Chief Business Officer | −5,100 | $43.81 |
| Aug 12, 2026 | John R. Moore | officer: General Counsel | −5,016 | $43.82 |
| Aug 12, 2026 | Alan J. Russell | director, officer: Chief Scientific Officer | −5,901 | $43.73 |
| Aug 13, 2026 | Joanne M. Donovan | officer: CMO | −2,919 | $43.41 |
- Bristol-Myers Squibb
First approved cardiac myosin inhibitor for symptomatic obstructive HCM
- Cytokinetics
FDA-approved cardiac myosin inhibitor MYQORZO now commercial for oHCM
- Sarepta Therapeutics
Dominant DMD franchise via gene therapy, exon skipping, and RNA medicine
- Tenaya Therapeutics
AAV9 gene therapy targeting MYBPC3-mutant HCM and PKP2-mutant ARVC
- Capricor Therapeutics
Allogeneic cell therapy targeting DMD cardiomyopathy; BLA under FDA review
- Wave Life Sciences
Stereopure RNA oligonucleotide platform; NDA-stage exon-53 DMD program
- PTC Therapeutics
Rare-disease biopharma with DMD portfolio and PKU growth product Sephience
- Rocket Pharmaceuticals
AAV gene therapy for inherited cardiomyopathies: Danon, PKP2-ACM, BAG3-DCM
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics | $42.71 | −4.05% | $4.79B | — | — | — | — |
| Bristol-Myers Squibb | $61.87 | −0.61% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Cytokinetics | $65.99 | −2.37% | $8.41B | — | — | 118.5 | −57.1% |
| Sarepta Therapeutics | $20.42 | −1.90% | $2.20B | — | 35.5 | 1.1 | −34.3% |
| Tenaya Therapeutics | $0.6713 | −1.60% | $148.0M | — | — | 110.9 | — |
| Capricor Therapeutics | $9.18 | −1.71% | $537.1M | — | — | — | — |
| Wave Life Sciences | $4.06 | −6.67% | $857.2M | — | — | 13.1 | −73.9% |
| PTC Therapeutics | $65.00 | −1.46% | $5.51B | — | 52.5 | 5.5 | +101.6% |
| Rocket Pharmaceuticals | $3.28 | −2.24% | $365.8M | — | — | — | — |
| Median | 13.7 | 35.5 | 9.3 | −34.3% |